tadalafil has been researched along with Pulmonary Arterial Hypertension in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (19.35) | 24.3611 |
| 2020's | 25 (80.65) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, KM; Doelberg, M; Feldman, J; Galiè, N; Gibbs, JSR; Grünig, E; Hoeper, MM; Martin, N; Mathai, SC; McLaughlin, VV; Perchenet, L; Poch, D; Saggar, R; Simonneau, G; Sitbon, O | 1 |
| Wang, Y; Zhang, L; Zhang, R | 1 |
| Crook, S; Dorn, ML; Frank, B; Hite, MD; Issapour, A; Ivy, DD; Krishnan, US; Rosenzweig, EB | 1 |
| Abe, K; Hatano, M; Kiely, DG; Koike, G; Takahashi, T; Tunmer, G | 1 |
| Dohi, K; Hirayama, M; Ito, H; Kabwe, JC; Ko, H; Maruyama, J; Maruyama, K; Mashimo, T; Mitani, Y; Miyasaka, Y; Nishimura, Y; Ohashi, H; Okamoto, R; Oshita, H; Otsuki, S; Oya, K; Sawada, H; Tsuboya, N; Yodoya, N; Zhang, E | 1 |
| Cockrill, BA; Ruopp, NF | 1 |
| Skoularigis, J; Starling, RC; Triposkiadis, F; Xanthopoulos, A | 1 |
| Watanabe, H | 1 |
| Buendía, JA; Guerrero Patiño, D; Lindarte, EF | 1 |
| Barberà, JA; Blair, C; Chakinala, MM; Frost, AE; Ghofrani, HA; Grünig, E; Hoeper, MM; Langley, J; McLaughlin, VV; Oudiz, RJ; Rosenkranz, S; Vonk-Noordegraaf, A; White, RJ | 1 |
| Argiento, P; Badagliacca, R; D'Alto, M; Farro, A; Golino, P; Naeije, R; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Vizza, CD | 1 |
| Barberà, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Hoeper, MM; Langley, J; McLaughlin, VV; Oudiz, RJ; Peacock, AJ; Rosenkranz, S; Rubin, LJ; Simonneau, G; Vachiery, JL | 1 |
| Locatelli, I; Petrovič, M | 1 |
| Blair, C; Coghlan, JG; Kuwana, M; Langley, J; Takahashi, T | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Bergot, E; Bertoletti, L; Bouvaist, H; Canuet, M; Clerson, P; Cottin, V; Gressin, V; Perchenet, L; Picard, F; Prévot, G; Simonneau, G; Sitbon, O | 1 |
| Chen, Z; Deng, X; Li, W; Peng, Y; Wang, Y; Xiao, Y; Xiao, Z; Zeng, Y | 1 |
| Burki, TK | 1 |
| Argiento, P; Badagliacca, R; Casu, G; Corda, M; Correale, M; D'Alto, M; Ghio, S; Golino, P; Greco, A; Lattanzio, M; Lo Giudice, F; Mercurio, V; Naeije, R; Paciocco, G; Papa, S; Prediletto, R; Romeo, E; Russo, MG; Tayar, A; Vitulo, P; Vizza, CD | 1 |
| Farber, HW; Schoenberg, NC | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Heresi, GA; Rao, Y | 1 |
| Aurtenetxe Pérez, A; Diago Cabezudo, JI; Escribano Subías, P; Gómez Climent, L; Perelló, MF; Pérez Olivares, C | 1 |
| Broderick, M; Champion, H; Kovacs, G; Mandras, S; Nelsen, A; Olschewski, H; Shen, E | 1 |
| Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N | 1 |
| Cascino, TM; McLaughlin, VV | 1 |
| Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L | 1 |
| Barberá, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiéry, JL | 1 |
| El-Kersh, K; Jalil, BA; Smith, JS | 1 |
| Bonnet, D; Dahdah, N; Ferguson-Sells, L; Landry, J; Li, B; Small, D | 1 |
| Miyasaka, A; Morino, Y; Suzuki, A; Takikawa, Y; Ueda, H; Yoshida, Y | 1 |
6 review(s) available for tadalafil and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Topics: Adult; Antihypertensive Agents; Endothelin Receptor Antagonists; Endothelins; Guanosine Monophosphate; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Nitric Oxide; Pulmonary Arterial Hypertension; Tadalafil; United States | 2022 |
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Topics: Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Guanosine Monophosphate; Guanylate Cyclase; Heart Failure; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Retrospective Studies; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Vasodilator Agents | 2022 |
Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.
Topics: Antihypertensive Agents; Bayes Theorem; Comparative Effectiveness Research; Drug Combinations; Drug Therapy, Combination; Epoprostenol; Humans; Male; Network Meta-Analysis; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome; Walk Test | 2020 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Humans; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil | 2021 |
Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Epoprostenol; Humans; Nitric Oxide; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil | 2021 |
10 trial(s) available for tadalafil and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Sulfonamides; Tadalafil | 2021 |
Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil; Treatment Outcome | 2022 |
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Tadalafil; Vasodilator Agents | 2019 |
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Risk Factors; Tadalafil; Vasodilator Agents; Ventricular Dysfunction, Left | 2019 |
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Topics: Adult; Comorbidity; Connective Tissue Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Phenylpropionates; Proportional Hazards Models; Pulmonary Arterial Hypertension; Pyridazines; Risk Assessment; Scleroderma, Systemic; Tadalafil; Treatment Outcome; Vasodilator Agents | 2020 |
Pharmacotherapy for pulmonary arterial hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Severity of Illness Index; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance | 2020 |
Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Epoprostenol; Female; Follow-Up Studies; Functional Status; Humans; Male; Middle Aged; Pulmonary Arterial Hypertension; Survival Rate; Tadalafil; Vasodilator Agents; Walk Test | 2020 |
Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Topics: Adult; Area Under Curve; Body Weight; Bosentan; Child; Female; Humans; Male; Pulmonary Arterial Hypertension; Tadalafil | 2022 |
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Topics: Aged; Antihypertensive Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyridazines; Tadalafil; Treatment Outcome | 2019 |
Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study.
Topics: Adolescent; Antihypertensive Agents; Area Under Curve; Bosentan; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Tadalafil | 2019 |
15 other study(ies) available for tadalafil and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report.
Topics: Adult; Antihypertensive Agents; Diagnostic Errors; Drug Therapy, Combination; High-Throughput Nucleotide Sequencing; Humans; Male; Phenylpropionates; Protein Serine-Threonine Kinases; Pulmonary Arterial Hypertension; Pulmonary Veno-Occlusive Disease; Pyridazines; Tadalafil; Vasodilator Agents | 2021 |
Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Tadalafil; Treatment Outcome | 2022 |
CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.
Topics: Animals; Bone Morphogenetic Protein Receptors, Type II; Clustered Regularly Interspaced Short Palindromic Repeats; Fibrosis; Humans; Hypertension, Pulmonary; Lung; Mice; Monocrotaline; Point Mutation; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Tadalafil | 2022 |
[Role of NO-cGMP-PKG axis in pulmonary arterial hypertension].
Topics: Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Tadalafil | 2022 |
Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
Topics: Child; Cost-Benefit Analysis; Humans; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Sildenafil Citrate; Tadalafil | 2023 |
Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Atrial Remodeling; Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Epoprostenol; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Risk Reduction Behavior; Tadalafil; Treatment Outcome; Vascular Resistance; Vasodilator Agents; Ventricular Function, Right; Ventricular Remodeling; Walk Test | 2020 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension.
Topics: Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Tadalafil | 2020 |
Ligation of patent ductus venosus in a child with pulmonary arterial hypertension and hypersplenism: A case report.
Topics: Aftercare; Antihypertensive Agents; Bosentan; Cardiomegaly; Child, Preschool; Combined Modality Therapy; Echocardiography; Humans; Hypersplenism; Ligation; Male; Portal Vein; Pulmonary Arterial Hypertension; Radiography, Thoracic; Tadalafil; Tomography, X-Ray Computed; Treatment Outcome; Vascular Malformations; Vascular Resistance; Vasodilator Agents | 2020 |
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Risk Assessment; Tadalafil; Time Factors; Treatment Outcome; Vasodilator Agents | 2020 |
When "AMBITION" Isn't Good Enough: Risk Status and Dual Oral Therapy in Pulmonary Arterial Hypertension.
Topics: Antihypertensive Agents; Hemodynamics; Humans; Pulmonary Arterial Hypertension; Risk Reduction Behavior; Tadalafil | 2021 |
Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION.
Topics: Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Tadalafil | 2021 |
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2019 |
A 34-Year-Old Woman With Hoarseness of Voice and an Abnormal Echocardiogram.
Topics: Adult; Dyspnea; Echocardiography; Female; Heart Atria; Heart Ventricles; Hoarseness; Humans; Laryngoscopy; Lung; Patient Care Management; Pulmonary Arterial Hypertension; Pulmonary Artery; Severity of Illness Index; Tadalafil; Tomography, X-Ray Computed; Treatment Outcome; Vasodilator Agents; Vocal Cord Paralysis | 2019 |
A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Cardiac Catheterization; Echocardiography; Echocardiography, Doppler; Endothelin Receptor Antagonists; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Liver Cirrhosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Sustained Virologic Response; Tadalafil; Treatment Outcome; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Right | 2020 |